PAUL BOYD: Open Payments
NPI 1699250886 · PALM SPRINGS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$638 in 31 payments from 15 companies in 2025. Trend: 2023 $891 · 2024 $913 · 2025 $638
Food & beverage: $638
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 8 | $141 |
| Amgen Inc. | 4 | $84 |
| Lilly USA, LLC | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 2 | $59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $52 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $27 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Novo Nordisk Inc | 1 | $21 |
Products named: OTEZLA, SPRAVATO, MOUNJARO, BREZTRI, VOQUEZNA, Veozah, PIFELTRO, REPATHA.
Industry payments across CA — which companies pay providers there.
